264 related articles for article (PubMed ID: 31303064)
1. Gene Therapy for Methylmalonic Acidemia: Past, Present, and Future.
Chandler RJ; Venditti CP
Hum Gene Ther; 2019 Oct; 30(10):1236-1244. PubMed ID: 31303064
[TBL] [Abstract][Full Text] [Related]
2. Pre-clinical efficacy and dosing of an AAV8 vector expressing human methylmalonyl-CoA mutase in a murine model of methylmalonic acidemia (MMA).
Chandler RJ; Venditti CP
Mol Genet Metab; 2012 Nov; 107(3):617-9. PubMed ID: 23046887
[TBL] [Abstract][Full Text] [Related]
3. Promoterless, Nuclease-Free Genome Editing Confers a Growth Advantage for Corrected Hepatocytes in Mice With Methylmalonic Acidemia.
Chandler RJ; Venturoni LE; Liao J; Hubbard BT; Schneller JL; Hoffmann V; Gordo S; Zang S; Ko CW; Chau N; Chiang K; Kay MA; Barzel A; Venditti CP
Hepatology; 2021 Jun; 73(6):2223-2237. PubMed ID: 32976669
[TBL] [Abstract][Full Text] [Related]
4. Long-term rescue of a lethal murine model of methylmalonic acidemia using adeno-associated viral gene therapy.
Chandler RJ; Venditti CP
Mol Ther; 2010 Jan; 18(1):11-6. PubMed ID: 19861951
[TBL] [Abstract][Full Text] [Related]
5. Liver-directed recombinant adeno-associated viral gene delivery rescues a lethal mouse model of methylmalonic acidemia and provides long-term phenotypic correction.
Carrillo-Carrasco N; Chandler RJ; Chandrasekaran S; Venditti CP
Hum Gene Ther; 2010 Sep; 21(9):1147-54. PubMed ID: 20486773
[TBL] [Abstract][Full Text] [Related]
6. Growth advantage of corrected hepatocytes in a juvenile model of methylmalonic acidemia following liver directed adeno-associated viral mediated nuclease-free genome editing.
Venturoni LE; Chandler RJ; Liao J; Hoffmann V; Ramesh N; Gordo S; Chau N; Venditti CP
Mol Genet Metab; 2022; 137(1-2):1-8. PubMed ID: 35868241
[TBL] [Abstract][Full Text] [Related]
7. Neutralizing Antibodies Against Adeno-Associated Viral Capsids in Patients with mut Methylmalonic Acidemia.
Harrington EA; Sloan JL; Manoli I; Chandler RJ; Schneider M; McGuire PJ; Calcedo R; Wilson JM; Venditti CP
Hum Gene Ther; 2016 May; 27(5):345-53. PubMed ID: 26790480
[TBL] [Abstract][Full Text] [Related]
8. Systemic Messenger RNA Therapy as a Treatment for Methylmalonic Acidemia.
An D; Schneller JL; Frassetto A; Liang S; Zhu X; Park JS; Theisen M; Hong SJ; Zhou J; Rajendran R; Levy B; Howell R; Besin G; Presnyak V; Sabnis S; Murphy-Benenato KE; Kumarasinghe ES; Salerno T; Mihai C; Lukacs CM; Chandler RJ; Guey LT; Venditti CP; Martini PGV
Cell Rep; 2017 Dec; 21(12):3548-3558. PubMed ID: 29262333
[TBL] [Abstract][Full Text] [Related]
9. Treatment of metabolic disorders using genomic technologies: Lessons from methylmalonic acidemia.
Venturoni LE; Venditti CP
J Inherit Metab Dis; 2022 Sep; 45(5):872-888. PubMed ID: 35766386
[TBL] [Abstract][Full Text] [Related]
10. Adenoviral-mediated correction of methylmalonyl-CoA mutase deficiency in murine fibroblasts and human hepatocytes.
Chandler RJ; Tsai MS; Dorko K; Sloan J; Korson M; Freeman R; Strom S; Venditti CP
BMC Med Genet; 2007 Apr; 8():24. PubMed ID: 17470278
[TBL] [Abstract][Full Text] [Related]
11. Gene therapy in a murine model of methylmalonic acidemia using rAAV9-mediated gene delivery.
Sénac JS; Chandler RJ; Sysol JR; Li L; Venditti CP
Gene Ther; 2012 Apr; 19(4):385-91. PubMed ID: 21776024
[TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy and safety of mRNA therapy in two murine models of methylmalonic acidemia.
An D; Frassetto A; Jacquinet E; Eybye M; Milano J; DeAntonis C; Nguyen V; Laureano R; Milton J; Sabnis S; Lukacs CM; Guey LT
EBioMedicine; 2019 Jul; 45():519-528. PubMed ID: 31303505
[TBL] [Abstract][Full Text] [Related]
13. TAT-MTS-MCM fusion proteins reduce MMA levels and improve mitochondrial activity and liver function in MCM-deficient cells.
Erlich-Hadad T; Hadad R; Feldman A; Greif H; Lictenstein M; Lorberboum-Galski H
J Cell Mol Med; 2018 Mar; 22(3):1601-1613. PubMed ID: 29265583
[TBL] [Abstract][Full Text] [Related]
14. Adenovirus-mediated gene delivery rescues a neonatal lethal murine model of mut(0) methylmalonic acidemia.
Chandler RJ; Venditti CP
Hum Gene Ther; 2008 Jan; 19(1):53-60. PubMed ID: 18052792
[TBL] [Abstract][Full Text] [Related]
15. A novel small molecule approach for the treatment of propionic and methylmalonic acidemias.
Armstrong AJ; Collado MS; Henke BR; Olson MW; Hoang SA; Hamilton CA; Pourtaheri TD; Chapman KA; Summar MM; Johns BA; Wamhoff BR; Reardon JE; Figler RA
Mol Genet Metab; 2021 May; 133(1):71-82. PubMed ID: 33741272
[TBL] [Abstract][Full Text] [Related]
16. A New Era for Rare Genetic Diseases: Messenger RNA Therapy.
Martini PGV; Guey LT
Hum Gene Ther; 2019 Oct; 30(10):1180-1189. PubMed ID: 31179759
[TBL] [Abstract][Full Text] [Related]
17. Systematic literature review and meta-analysis on the epidemiology of methylmalonic acidemia (MMA) with a focus on MMA caused by methylmalonyl-CoA mutase (mut) deficiency.
Almási T; Guey LT; Lukacs C; Csetneki K; Vokó Z; Zelei T
Orphanet J Rare Dis; 2019 Apr; 14(1):84. PubMed ID: 31023387
[TBL] [Abstract][Full Text] [Related]
18. Perspectives on methylmalonic acidemia resulting from molecular cloning of methylmalonyl CoA mutase.
Ledley FD
Bioessays; 1990 Jul; 12(7):335-40. PubMed ID: 1975493
[TBL] [Abstract][Full Text] [Related]
19. Aberrant methylmalonylation underlies methylmalonic acidemia and is attenuated by an engineered sirtuin.
Head PE; Myung S; Chen Y; Schneller JL; Wang C; Duncan N; Hoffman P; Chang D; Gebremariam A; Gucek M; Manoli I; Venditti CP
Sci Transl Med; 2022 May; 14(646):eabn4772. PubMed ID: 35613279
[TBL] [Abstract][Full Text] [Related]
20. Biochemical and anaplerotic applications of in vitro models of propionic acidemia and methylmalonic acidemia using patient-derived primary hepatocytes.
Collado MS; Armstrong AJ; Olson M; Hoang SA; Day N; Summar M; Chapman KA; Reardon J; Figler RA; Wamhoff BR
Mol Genet Metab; 2020 Jul; 130(3):183-196. PubMed ID: 32451238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
